Takeda Pharmaceutical, Affymax Conclude Licensing Agreement for Hematide, Renal/Malignant Anemia Treatment Agent.Tokyo, Japan, Feb 14, 2006 - (JCN) - Takeda Pharmaceutical announced on February 13 that it has entered into an exclusive agreement with Affymax for Hematide, Affymax's proprietary agent indicated for the treatment of renal and malignant anemia. Under the agreement terms, Takeda will be able to exclusively develop and market the agent in Japan. In the meantime Adv. 1. in the meantime - during the intervening time; "meanwhile I will not think about the problem"; "meantime he was attentive to his other interests"; "in the meantime the police were notified" meantime, meanwhile , Takeda will make an upfront payment of $17 million as well as purchasing Affymax's shares for $10 million. Further, Takeda will make milestone payments and royalties to Affymax upon successful development and commercialization of the agent. Hematide is a synthetic peptide erythropoiesis-stimulating agent that has a property to increase the number of erythrocytes Erythrocytes Red blood cells. Mentioned in: Bartonellosis erythrocytes (ē·rithˑ·rō·sīts), n.pl red blood cells. (red blood cells Red blood cells Cells that carry hemoglobin (the molecule that transports oxygen) and help remove wastes from tissues throughout the body. Mentioned in: Bone Marrow Transplantation red blood cells ). Currently, Affymax is conducting a phase II clinical trial Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II of the agent for the treatment of renal and malignant anemia. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion